负荷剂量氯吡格雷治疗进展性脑卒中的疗效分析

Analysis on the Efficacy of Loading Dose of Clopidogrel in the Treatment of Progressive Stroke

目的分析负荷剂量氯吡格雷治疗进展性脑卒中患者的临床效果。方法选取2018年1月至2018年7月期间我院收治的30例进展性脑卒中患者作为研究对象,随机分为两组各15例。对照组患者给予常规治疗,观察组患者在常规治疗基础上给予负荷剂量氯吡格雷治疗。比较两组患者治疗前后的神经功能缺损评分、日常生活活动能力评分以及凝血功能。结果治疗前,两组患者的NIHSS评分、 BI评分比较无统计学差异(P>0.05);治疗后,观察组患者的NIHSS评分显著低于对照组, BI评分显著高于对照组,差异具有统计学意义(P <0.05)。两组患者治疗前后的血小板计数(PLT)、活化部分凝血活酶时间(APTT)及凝血酶原时间(PT)等凝血功能指标均无统计学差异(P>0.05)。结论负荷剂量氯吡格雷治疗进展性脑卒中可有效改善患者的神经功能和日常生活活动能力,对患者的预后改善具有积极影响,值得临床推广。

Objective To analyze the clinical effect of loading dose of clopidogrel in the treatment of patients with progressive stroke. Methods 30 cases of patients with progressive stroke admitted to our hospital from January 2018 to July 2018 were selected as research objects, and randomly divided into two groups, with 15 cases in each group. Patients in the control group received regular therapy, while patients in the observation group were treated with loading dose of clopidogrel on the basis of regular therapy. Before and after treatment, the coagulation function, as well as the scores of neurological deficits and activities of daily living were compared between the two groups. Results Before treatment, no statistical difference was found between the two groups in the NIHSS score and BI score (P >0.05);After treatment, the NIHSS score of the observation group was significantly lower than that of the control group, and the BI score was significantly higher than that of the control group, with statistical differences (P <0.05). Before and after treatment, no statistical difference was found between the two groups in the coagulation function indicators including the platelet count (PLT), activated partial thromboplastin time (APTT) and prothrombin time (PT), all P >0.05. Conclusions Loading dose of clopidogrel in the treatment of progressive stroke can effectively improve the neurological function and activities of daily living of patients, and has a positive impact on the improvement of patient's prognosis, which is worthy of clinical promotion.